{"id":7233,"date":"2024-08-01T10:15:00","date_gmt":"2024-08-01T08:15:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes-gar-vidare-med-nasta-dosgrupp-enligt-plan\/"},"modified":"2024-08-01T10:15:00","modified_gmt":"2024-08-01T08:15:00","slug":"nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes-gar-vidare-med-nasta-dosgrupp-enligt-plan","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes-gar-vidare-med-nasta-dosgrupp-enligt-plan\/","title":{"rendered":"Nanexas fas I-studie med NEX-22 inom typ 2-diabetes g\u00e5r vidare med n\u00e4sta dosgrupp enligt plan"},"content":{"rendered":"
\n

Nanexa AB meddelar idag att bolagets fas-I-studie f\u00f6r typ 2-diabetes inom NEX-22 projektet fortg\u00e5r enligt plan med ytterligare doseskalering med sin dep\u00e5formulering av GLP-1-analogen liraglutid.<\/strong><\/p>\n<\/div>\n

\n

Studiens utsedda kommitt\u00e9 f\u00f6r doseskalering har kunnat ta beslut att forts\u00e4tta med \u00f6kad dosering i n\u00e4sta behandlingsgrupp, baserat p\u00e5 resultat fr\u00e5n patienter i den f\u00f6rsta dosgruppen.<\/p>\n

\u201cVi gl\u00e4ds \u00e5t att ha de f\u00f6rsta kliniska resultaten f\u00f6r NEX-22 i patienter med typ-2-diabetes d\u00e4r vi tydligt ser en f\u00f6rdr\u00f6jd fris\u00e4ttning med en f\u00f6rl\u00e4ngd farmakokinetisk profil samtidigt som s\u00e4kerhetsprofilen observerats med endast milda reaktioner vid injektionsst\u00e4llet\u201d, s\u00e4ger David Westberg, VD p\u00e5 Nanexa. \u201dVi forts\u00e4tter nu att generera viktig information f\u00f6r NEX-22 projektets framdrift, men \u00f6ppnar \u00e4ven upp m\u00f6jligheter f\u00f6r andra GLP-1-l\u00e4kemedel med PharmaShell\u00ae-teknologin\u201d.<\/p>\n

I studien ges dep\u00e5formuleringen av NEX-22 som en injektion under huden. Studien \u00e4r designad att inkludera flera p\u00e5 varandra f\u00f6ljande grupper med eskalerande doser och syftar till att utv\u00e4rdera farmakokinetisk profil, s\u00e4kerhet och tolerabilitet f\u00f6r olika doser.<\/p>\n

Glukagonliknande peptid-1 (GLP-1) receptoragonister \u00e4r en klass av l\u00e4kemedel f\u00f6r behandling av typ 2-diabetes och fetma. Liraglutid \u00e4r en GLP-1-analog som ing\u00e5r i de idag marknadsf\u00f6rda produkterna Victoza och Saxenda f\u00f6r dagliga injektioner.<\/p>\n<\/div>\n

\n

F\u00f6r mer information kontakta:<\/strong><\/p>\n

\n

David Westberg \u2013 VD, Nanexa AB (publ)\u00a0
Telefon: 0709-42 83 03
E-post:\u00a0david.westberg@nanexa.se<\/a>
www.nanexa.com<\/a><\/p>\n

Bolagets Certified Adviser \u00e4r Carnegie Investment Bank AB (publ).<\/p>\n<\/div>\n

\n

Om Nanexa AB (publ)<\/strong><\/p>\n

\n

Nanexa \u00e4r ett l\u00e4kemedelsbolag som utvecklar injicerbara l\u00e4kemedel baserade p\u00e5 det patenterade och innovativa drug delivery-systemet PharmaShell\u00ae \u2013 ett system som m\u00f6jligg\u00f6r n\u00e4sta generations l\u00e5ngverkande injicerbara l\u00e4kemedel med h\u00f6g drug load, tillverkade med atomlagerprecision. Nanexa utvecklar egna produkter och har dessutom samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland Novo Nordisk och AstraZeneca.<\/p>\n

Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n

\n

Bifogade filer<\/strong><\/p>\n

\n

Nanexas fas I-studie med NEX-22 inom typ 2-diabetes g\u00e5r vidare med n\u00e4sta dosgrupp enligt plan<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Nanexa AB meddelar idag att bolagets fas-I-studie f\u00f6r typ 2-diabetes inom NEX-22 projektet fortg\u00e5r enligt plan med ytterligare doseskalering med sin dep\u00e5formulering av GLP-1-analogen liraglutid.<\/p>\n","protected":false},"template":"","class_list":["post-7233","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"\nNanexas fas I-studie med NEX-22 inom typ 2-diabetes g\u00e5r vidare med n\u00e4sta dosgrupp enligt plan - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes-gar-vidare-med-nasta-dosgrupp-enligt-plan\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexas fas I-studie med NEX-22 inom typ 2-diabetes g\u00e5r vidare med n\u00e4sta dosgrupp enligt plan - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Nanexa AB meddelar idag att bolagets fas-I-studie f\u00f6r typ 2-diabetes inom NEX-22 projektet fortg\u00e5r enligt plan med ytterligare doseskalering med sin dep\u00e5formulering av GLP-1-analogen liraglutid.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes-gar-vidare-med-nasta-dosgrupp-enligt-plan\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes-gar-vidare-med-nasta-dosgrupp-enligt-plan\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes-gar-vidare-med-nasta-dosgrupp-enligt-plan\\\/\",\"name\":\"Nanexas fas I-studie med NEX-22 inom typ 2-diabetes g\u00e5r vidare med n\u00e4sta dosgrupp enligt plan - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2024-08-01T08:15:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes-gar-vidare-med-nasta-dosgrupp-enligt-plan\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes-gar-vidare-med-nasta-dosgrupp-enligt-plan\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes-gar-vidare-med-nasta-dosgrupp-enligt-plan\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexas fas I-studie med NEX-22 inom typ 2-diabetes g\u00e5r vidare med n\u00e4sta dosgrupp enligt plan\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexas fas I-studie med NEX-22 inom typ 2-diabetes g\u00e5r vidare med n\u00e4sta dosgrupp enligt plan - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes-gar-vidare-med-nasta-dosgrupp-enligt-plan\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexas fas I-studie med NEX-22 inom typ 2-diabetes g\u00e5r vidare med n\u00e4sta dosgrupp enligt plan - Nanexa AB","og_description":"Nanexa AB meddelar idag att bolagets fas-I-studie f\u00f6r typ 2-diabetes inom NEX-22 projektet fortg\u00e5r enligt plan med ytterligare doseskalering med sin dep\u00e5formulering av GLP-1-analogen liraglutid.","og_url":"https:\/\/nanexa.com\/mfn_news\/nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes-gar-vidare-med-nasta-dosgrupp-enligt-plan\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes-gar-vidare-med-nasta-dosgrupp-enligt-plan\/","url":"https:\/\/nanexa.com\/mfn_news\/nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes-gar-vidare-med-nasta-dosgrupp-enligt-plan\/","name":"Nanexas fas I-studie med NEX-22 inom typ 2-diabetes g\u00e5r vidare med n\u00e4sta dosgrupp enligt plan - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2024-08-01T08:15:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes-gar-vidare-med-nasta-dosgrupp-enligt-plan\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes-gar-vidare-med-nasta-dosgrupp-enligt-plan\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/nanexas-fas-i-studie-med-nex-22-inom-typ-2-diabetes-gar-vidare-med-nasta-dosgrupp-enligt-plan\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexas fas I-studie med NEX-22 inom typ 2-diabetes g\u00e5r vidare med n\u00e4sta dosgrupp enligt plan"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/7233","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=7233"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}